US Patent

US11364212 — Methods for treating inflammatory skin conditions

Method of Use · Assigned to Dr Reddys Laboratories Ltd · Expires 2039-01-07 · 13y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating inflammatory skin conditions by administering a reduced dose of minocycline to a subject.

USPTO Abstract

The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4043`	—	minocycline-hydrochloride

Patent Metadata

Patent number: US11364212
Jurisdiction: US
Classification: Method of Use
Expires: 2039-01-07
Drug substance claim: No
Drug product claim: No
Assignee: Dr Reddys Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.